Sinphar Deepens Partnerships with Japanese Firms, Expanding in Digestive and Cancer Drug Markets

Q: What are the key facts in this article?

Taiwanese generic drugmaker Sinphar has signed a new agency agreement with Japan's Magmitt Pharmaceutical for digestive system drugs in Taiwan. It is also advancing contract manufacturing for cancer drugs with Japan's Daito to expand its footprint in the Asian market.

Q: What is the direct answer?

Taiwanese generic drugmaker Sinphar has signed a new agency agreement with Japan's Magmitt Pharmaceutical for digestive system drugs in Taiwan. It is also advancing contract manufacturing for cancer drugs with Japan's Daito to expand its footprint in the Asian market.

Q: What is the source and date?

Source: https://www.cna.com.tw/news/afe/202606120356.aspx | Date: Date unavailable

(Central News Agency reporter He Xiuling, Taipei, 12th) Generic pharmaceutical manufacturer Sinphar recently signed a new agency agreement with Japan's Magmitt Pharmaceutical for the Taiwan market rights to a digestive system drug. After its introduction, it is expected to strengthen Sinphar's product line. In addition, Sinphar is negotiating cooperation agreements with Japanese pharmaceutical companies regarding cancer drug contract manufacturing, technology licensing, and market sales, expanding its footprint in the Japanese and Asian markets. Sinphar pointed out in a press release today that Vice Chairman Lee Yi-da and General Manager Pai You-lang recently visited partners in Japan, continuing the exchange outcomes from the 2025 CPHI Japan (International Convention on Pharmaceutical Ingredients Japan) exhibition. They are negotiating with multiple Japanese companies on cooperation cases such as drug agency, contract manufacturing, joint development, technology licensing, and market sales. Pai You-lang stated that Sinphar has signed a new sales agency right for the Taiwan market for a digestive system drug with Japan's Magmitt Pharmaceutical, a partner of many years. This product has long held a certain market share and reputation in similar markets in Japan. It is expected that bringing it into Taiwan will help enhance market competitiveness and reinforce Sinphar's product layout in the field of digestive system medications. Sinphar noted that the demand for digestive system drugs is relatively stable. According to historical medication statistics from the National Health Insurance Administration, related drugs have long been among the main medication categories for Taiwanese people, with constipation medication usage ranking near the top. As Taiwan enters a super-aged society, the market demand for related drugs is expected to continue growing. Besides the agency business, Sinphar is also continuing to deepen its cooperative relationship with Japan's Daito. Sinp

Sinphar Deepens Partnerships with Japanese Firms, Expanding in Digestive and Cancer Drug Markets

AI Summary (NQ-processed)

AI Analysis